Cooley LLP announced today that it represented Jazz Pharmaceuticals plc in its $125 million acquisition of the worldwide development, manufacturing and commercial rights to ADX-N05 from Aerial BioPharma, LLC. ADX-N05 is being developed for the treatment of excessive daytime sleepiness in patients suffering from narcolepsy.
The Cooley team representing Jazz included partner Marya Postner and associates Bin Wang and Holly Holloway (life sciences); partner Jennifer DiNucci, special counsel Brian Wheeler and associate Christine Liu (M&A); partner Chadwick Mills (capital markets); partners Bill Morrow and Mark Windfeld-Hansen (tax); partners Mischi a Marca and Michael Tollini and associates Amanda Fant and Jason Savich (credit finance); partner Francis Fryscak (antitrust); partner Natasha Leskovsek (health care & life sciences regulatory); and partner Gregory Tenhoff and associate Tyler Onitsuka (employment).
Related Posts:
- Cooley Advises Jazz Pharmaceuticals plc on Rule 144A Offering of $575 Million of Exchangeable Senior Notes
- Cooley Advises Jazz Pharmaceuticals in $314.4 Million Offering
- Cooley Advises Jazz Pharmaceuticals in Pending Acquisition of EUSA Pharma for up to $700 Million
- Cooley Represents AcelRx Pharmaceuticals in Public Offering
- Cooley Advises CHC Group on its $310 Million Initial Public Offering and Refinancing Transactions